Catastrophic Costs Among Tuberculosis-affected Households in Zimbabwe: A National Health Facility-based Survey
Overview
Tropical Medicine
Authors
Affiliations
Objectives: To determine the incidence and major drivers of catastrophic costs among TB-affected households in Zimbabwe.
Methods: We conducted a nationally representative health facility-based survey with random cluster sampling among consecutively enrolled drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) patients. Costs incurred and income lost due to TB illness were captured using an interviewer-administered standardised questionnaire. We used multivariable logistic regression to determine the risk factors for experiencing catastrophic costs.
Results: A total of 841 patients were enrolled and were weighted to 900 during data analysis. There were 500 (56%) males and 46 (6%) DR-TB patients. Thirty-five (72%) DR-TB patients were HIV co-infected. Overall, 80% (95% CI: 77-82) of TB patients and their households experienced catastrophic costs. The major cost driver pre-TB diagnosis was direct medical costs. Nutritional supplements were the major cost driver post-TB diagnosis, with a median cost of US$360 (IQR: 240-600). Post-TB median diagnosis costs were three times higher among DR-TB (US$1,659 [653-2,787]) than drug DS-TB-affected households (US$537 [204-1,134]). Income loss was five times higher among DR-TB than DS-TB patients. In multivariable analysis, household wealth was the only covariate that remained significantly associated with catastrophic costs: The poorest households had 16 times the odds of incurring catastrophic costs versus the wealthiest households (adjusted odds ratio [aOR: 15.7 95% CI: 7.5-33.1]).
Conclusion: The majority of TB-affected households, especially those affected by DR-TB, experienced catastrophic costs. Since the major cost drivers fall outside the healthcare system, multi-sectoral approaches to TB control and linking TB patients to social protection may reduce catastrophic costs.
Jeyashree K, Thangaraj J, Shanmugasundaram D, Giridharan S, Pandey S, Shanmugasundaram P Glob Health Res Policy. 2024; 9(1):51.
PMID: 39648213 PMC: 11626761. DOI: 10.1186/s41256-024-00392-9.
Waterous P, Chingono R, Mackworth-Young C, Nyamayaro C, Kandiye F, Marambire E PLOS Glob Public Health. 2024; 4(11):e0003659.
PMID: 39546535 PMC: 11567634. DOI: 10.1371/journal.pgph.0003659.
Patient costs for drug-resistant TB diagnosis and pre-treatment evaluation in North India.
Das S, Kumar R, Krishnan A, Kant S, Mohan A Public Health Action. 2024; 14(3):129-134.
PMID: 39239156 PMC: 11373743. DOI: 10.5588/pha.24.0018.
Timire C, Houben R, Pedrazzoli D, Ferrand R, Calderwood C, Bond V PLOS Glob Public Health. 2024; 4(6):e0002745.
PMID: 38848427 PMC: 11161058. DOI: 10.1371/journal.pgph.0002745.
Fuady A, Arifin B, Yunita F, Rauf S, Fitriangga A, Sugiharto A PLOS Glob Public Health. 2024; 4(1):e0002489.
PMID: 38190416 PMC: 10773931. DOI: 10.1371/journal.pgph.0002489.